Showing 8411-8420 of 18147 results for "".
- New Published Data Demonstrates KidneyIntelX™ Has Broad Implications for Winning War on Chronic Kidney Dseasehttps://reachmd.com/news/new-published-data-demonstrates-kidneyintelxtm-has-broad-implications-for-winning-war-on-chronic-kidney-dsease/2456931/Electronic health record deployment of KidneyIntelX was associated with clinical actions that slowed progression of chronic kidney disease and improved Type 2 diabetes control in just 12 monthsResults demonstrated a 61% increa
- FDA Broadens Semaglutide Use to Tackle Kidney Disease and Cardio Riskshttps://reachmd.com/news/fda-broadens-semaglutide-use-to-tackle-kidney-disease-and-cardio-risks/2475156/The FDA’s recent decision to expand semaglutide’s indication to include chronic kidney disease in patients with type 2 diabetes, as detailed in
- Exploring the Link Between Dietary Diabetes Risk Reduction and Cancer Riskhttps://reachmd.com/news/exploring-the-link-between-dietary-diabetes-risk-reduction-and-cancer-risk/2484757/A new systematic review and meta-analysis of 19 observational cohorts found that high adherence to the dietary diabetes risk reduction score (DRRD) is
- MCG Scientists Secure $1.5 Million Grant to Treat Diabetic Retinopathyhttps://reachmd.com/news/mcg-scientists-secure-15-million-grant-to-treat-diabetic-retinopathy/2468163/Scientists at the Medical College of Georgia at Augusta University are searching for a new treatment target for a common complication of diabetes that can cause retinal blood vessels
- Tirzepatide Cuts Risk of Diabetes by 94% in Adults with Prediabetes and Obesity or Overweighthttps://reachmd.com/news/tirzepatide-cuts-risk-of-diabetes-by-94-in-adults-with-prediabetes-and-obesity-or-overweight/2467872/CNN — A three-year study of tirzepatide – a medication approved in the US as Mounjaro for diabetes and Zepbound for weight loss – found that when adults who had predia
- A New Era in Obesity and Diabetes Management: GLP-1 Receptor Agonistshttps://reachmd.com/news/a-new-era-in-obesity-and-diabetes-management-glp-1-receptor-agonists/2476047/Innovative GLP-1 receptor agonists are heralding a new frontier in obesity and diabetes management, offering potent weight loss via appetite modulation but demanding vigilant attention to gastrointestinal discomfort and muscle weakness. The ability of GLP-1 drugs to
- AI-Driven Tool Offers Contactless Screening for Hypertension and Diabeteshttps://reachmd.com/news/ai-driven-tool-offers-contactless-screening-for-hypertension-and-diabetes/2468604/A new AI-powered tool has shown promise for fast, non-invasive screening of high blood pressure and diabetes, potentially paving the way for at-home, no-contact monitoring. Presented as a preliminary study at the American Heart Association’s Scientific Sessions 2024, this system uses high-speed v
- Exploring the Dual Benefits of GLP-1 Receptor Agonists in Diabetes and Cancer Risk Reductionhttps://reachmd.com/news/exploring-the-dual-benefits-of-glp-1-receptor-agonists-in-diabetes-and-cancer-risk-reduction/2474893/As obesity and diabetes converge to amplify cancer risk in routine practice, clinicians must note that this indica
- Alcohol Is Driving a Half-Dozen Types of Cancer in the U.S., Study Findshttps://reachmd.com/news/alcohol-is-driving-a-half-dozen-types-of-cancer-in-the-us-study-finds/2467604/Alcohol has long been classified as a cancer-causing substance, but a study out Thursday gives a clearer sense of just how many cancer cases and deaths may be driven by drinking. Researchers from the American Cancer Society and
- New Assessment for Type 2 Systemic Lupus Erythematosus Symptomshttps://reachmd.com/news/new-assessment-for-type-2-systemic-lupus-erythematosus-symptoms/2463089/In a new study, researchers looked to better understand and evaluate the range of s